This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Nooglutyl (Nooglutil)

Emerging

Obscure Russian glutamate-axis nootropic — N-(5-hydroxynicotinoyl)-L-glutamic acid, developed at the Zakusov State Institute…

Aliases (10)
Nooglutyl · Nooglutil · Nooglutyl · Ноотропил-эстер? — no · distinct · Ноогл · N-(5-hydroxynicotinoyl)-L-glutamic acid · 5-OH-nicotinoyl-L-glutamic acid · IBKhPh-25 · ИБХФ-25
TYPICAL DOSE
100–200 mg/day
Daily
ROUTE
Oral (tablet)
Oral
CYCLE
Not well-characterized
As prescribed
STORAGE
Room temp; original container
Room temp

Overview

What is Nooglutyl (Nooglutil)?

Nooglutyl is a Russian-developed nootropic structurally related to glutamic acid, designed as an AMPA receptor positive modulator and memory enhancer. It is marketed for amnesia, cognitive impairment, and post-stroke recovery in Russia.

Key Benefits

Reported to improve memory acquisition, consolidation, and retrieval in animal models of amnesia. Used clinically in Russia for cognitive deficits associated with brain injury, stroke, and neurodegeneration; limited Western data.

Mechanism of Action

Acts as a positive modulator at AMPA-subtype glutamate receptors, slowing receptor desensitization and prolonging excitatory postsynaptic currents to facilitate long-term potentiation in hippocampal neurons.

Brand options4 known
NooglutylNooglutilNooglutylIBKhPh-25

StatusRussian Rx (cerebrovascular insufficiency, MCI, post-stroke cognitive recovery indication per Russian Pharmacological Committee dossier). Unscheduled in US (no FDA registration, no DEA scheduling). Not on EU register. Not on WADA prohibited list. Not a DSHEA-eligible dietary ingredient. Effectively gray-market or specialty Russian-import-only outside CIS.

Peptide Interactions

Citicoline / Alpha-GPC
Synergistic

(in the canonical stack): Generic choline cofactor for any AMPA/cholinergic-adjacent nootropic. Probably useful but not specifically studied with nooglutyl.

Cerebrolysin
Synergistic

(in the canonical stack quarterly): Different mechanism (peptide trophic) — theoretical synergy on the neuroprotective axis. No specific Russian co-prescript…

Noopept
Avoid

Significant mechanism overlap (AMPA modulation + neuroprotective framing). Stacking the two is mechanism-redundant. Pick one.

Multiple racetams simultaneously
Avoid

Same logic — partial AMPA + cholinergic mechanism overlap, diminishing returns.

NMDA antagonists / dissociatives
Avoid

Theoretical pharmacological antagonism with the NMDA-modulator arm. Not empirically studied.

Quality Indicators

Pharmacy-dispensed, intact packaging

Prescription tablets in original sealed packaging from a licensed pharmacy.

!

Generic vs branded

Generics are usually fine but bioavailability can vary slightly; track if you switch.

Unbranded blister or counterfeit risk

Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.

What to Expect

  • Day 1
    PK-driven acute peak per administration. Verify dose tolerated.
  • Week 1
    Steady-state reached for most daily-dosed pharma.
  • Week 2-4
    Therapeutic effect established; titration window if needed.
  • Long-term
    Periodic monitoring per drug class (labs, BP, ECG as applicable).

Side Effects & Safety

  • Per Russian sources: Minimal documented adverse effects at therapeutic doses. Occasional mild GI upset, mild headache, mild irritability — generic nootropic-class side effects.
  • Western pharmacovigilance signal: Effectively zero (compound is essentially unused outside Russia).
  • Rare-serious: No published case reports of serious adverse events. But absence of evidence here is partly absence of exposure — population-scale safety data does not exist.
  • Specific watch periods: N/A (no Western clinical use).

Honest framing: Side-effect profile appears clean from Russian sources but the Western evidence base is too thin to make confident safety statements at the population level.

References

Voronina TA et al. — Zakusov Institute nooglutyl pharmacology papers

pubmed.ncbi.nlm.nih.gov

foundational animal pharmacology, Russian-language primary literature with English abstracts.

View Study

Seredenin SB et al. — Zakusov Institute conceptual framing of CMP/PMP balance and Russian nootropic class

pubmed.ncbi.nlm.nih.gov

institutional context for the Russian nootropic taxonomy.

View Study

Russian Pharmacological Committee — Nooglutyl marketing authorization dossier

rlsnet.ru

basis for Russian Rx authorization in cerebrovascular insufficiency.

View Study

RUPharma — Nooglutyl product page (when in stock)

rupharma.com

primary gray-market source, intermittent availability.

View Study

CosmicNootropic — Nooglutyl product page (when in stock)

cosmicnootropic.com

backup gray-market source.

View Study
Was this helpful?
Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…
Continue: Extended research →
Our verdict, decision matrix, deep dives, controversies, sources

Related compounds

Cross-referenced from Nooglutyl (Nooglutil)

More in Pharmaceutical · Oral

94 compounds in bucket